Alector Shares Outstanding 2017-2021 | ALEC

Alector shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Alector Annual Shares Outstanding
(Millions of Shares)
2020 78
2019 62
2018 11
2017 9
2016 7
Alector Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 80
2021-03-31 79
2020-12-31 78
2020-09-30 79
2020-06-30 78
2020-03-31 75
2019-12-31 62
2019-09-30 68
2019-06-30 67
2019-03-31 44
2018-12-31 12
2018-09-30 11
2018-06-30 11
2018-03-31 11
2017-12-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.940B $0.021B
Alector Inc. is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Its product portfolio includes AL001, AL101, Al002 and AL003 which are in clinical stage. Alector Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29